Meet the team
The company was founded in 2011 by Frédéric Sedel, MD, PhD, a leading neurologist and neuroscientist; and Guillaume Brion, who has 25 years of experience in drug development and clinical research in the pharmaceutical industry.
MedDay currently has molecules in development for treatment of multiple sclerosis, autism and Alzheimer’s disease.
MedDay addresses areas of unmet need in neurological and psychiatric diseases through the brain metabolism. This approach relies on unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism.